Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia

INCLUSION CRITERIA : * Patients with nosocomial and/or healthcare-associated bacteremia with Gram-positive cocci in clusters * Confirmed to be meticillin-resistant S. aureus using a GeneXpert rapid molecular test * Aged 18 years or older * Who have given their written consent when this is possible or someone from his/her family, or if not possible, emergency inclusion * Who can receive follow-up for the entire duration of the study, i.e. 90 days EXCLUSION CRITERIA : * Known allergy to vancomycin or daptomycin * Women who are pregnant or breast-feeding * Patients who have received vancomycin treatment for more than 48 hours between the diagnostic blood culture and randomization * Specific sites of infection: pneumonia, meningitis, brain abscess, osteitis, polymicrobial infection * Life expectancy considered to be less than 72 hours * Severe hepatic impairment (Child C) * Short-term intravascular catheters which cannot be removed immediately EXCLUSION CRITERIA between D1 and D5 inclusive : * Specific sites of infection: osteitis diagnosed between D1 and D5 inclusive * Permanent foreign material infection (endovascular stents, replacement heart valves or joints, pace maker etc.) which cannot be removed within 36 hours of the first dose of the study drug